Investing in Humigent

Life sciences run on high-stakes decisions. Which physicians should a field team prioritize? Why is a launch underperforming in one geography but not another? Which access, claims, formulary, EMR, Rx, field, and market signals actually explain what is happening? And, most importantly, what should the commercial, medical, or access team do next? For years, the answer has lived across dashboards, spreadsheets, consulting decks, data warehouses, market research readouts, and the heads of domain experts. The industry has no shortage of data. It has no shortage of analytics. What it lacks is a trusted intelligence layer that can connect messy enterprise data to the decisions life sciences teams actually need to make.

That is why we are excited to announce First Rays Ventures' investment in Humigent.

Our thesis at First Rays is that the next wave of enterprise AI will not be won by generic copilots alone. In regulated, complex, high-consequence industries, AI needs to be domain-native, auditable, workflow-aware, and deployable inside the enterprise's existing operating model. The winners will not simply generate answers. They will reason over context, expose the logic behind recommendations, escalate ambiguity to humans, and help organizations act with confidence.

Humigent is building exactly that for life sciences. The company combines a vertical life sciences language model, specialized agents, a domain-specific semantic layer, and an auditable reasoning architecture to help pharma and biotech teams move from insight to action. Instead of treating AI as a black-box interface on top of existing analytics, Humigent is building a decision intelligence system designed for the realities of life sciences: fragmented data, compliance constraints, domain-specific terminology, human review, and the need for traceability.

This matters because life sciences AI is not a demo problem. It is a production problem. A generic model can summarize a document or answer a narrow question. But life sciences workflows require something much harder: understanding what "HCP segmentation," "access pull-through," "launch readiness," "medical field insight," or "formulary change" means in context; connecting signals across teams and systems; producing outputs that can be explained; and ensuring humans retain decision rights when ambiguity or risk is high.

Humigent's wedge is to start where the enterprise pain is most acute: commercial and medical decision-making in pharma and biotech. Products like One Customer Universe, GeoForecast, Dashboard Lens, Insights Navigator, Field Voice, MSL Voice, and Data Lens point to a broader ambition: not another dashboard, but an agentic intelligence layer that can unify signals, surface drivers, recommend actions, and create a durable audit trail across the decision lifecycle.

That architecture maps directly to where we believe enterprise AI is heading. As AI moves from experimentation to production, enterprises will need systems of control around agentic work: data grounding, reasoning traces, policy, governance, observability, human escalation, and auditability. In other words, the value shifts from "can the model answer?" to "can the enterprise trust, verify, govern, and operationalize the answer?"

Humigent understands this shift. The team brings deep life sciences, AI, data strategy, analytics, and enterprise deployment experience. Founder/CEO Ram Sharma previously founded Analytical Wizards, which was acquired in 2022, and the broader leadership team brings decades of operating experience across pharma analytics, commercial strategy, market research, medical affairs, enterprise AI, and product engineering. This is important because vertical AI companies are not built by model wrappers alone. They are built by teams that know the workflow, the data, the buyer, the compliance surface, and the organizational path to adoption.

We believe Humigent sits at the intersection of three large shifts: the rise of agentic AI, the need for domain-specific enterprise intelligence, and the increasing demand for governed, explainable AI in regulated industries. Enterprise AI does not scale on models alone. It needs governed data, cost controls, and context that connects AI to how businesses actually operate.

Life sciences organizations do not need more disconnected tools. They need intelligence systems that can help them see what others miss, understand why it matters, and act before the opportunity passes. That is the future Humigent is building.

We are thrilled to partner with Ram Sharma and the entire Humigent team as they build the agentic intelligence layer for high-stakes life sciences decisions.

Read more: https://humigent.ai/resource/humigent-raises-series-a-to-build-ai-intelligence-for-life-sciences/